Research Article

Antagonism Between Antibiotics Frequently Used in The Treatment of Staphylococcus aureus Infections and The Hypertensive Drug L-Captopril

Volume: 44 Number: 1 March 30, 2022
EN

Antagonism Between Antibiotics Frequently Used in The Treatment of Staphylococcus aureus Infections and The Hypertensive Drug L-Captopril

Abstract

Objective: Captopril is a long-acting human angiotensin-converting enzyme (ACE) inhibitor that has been used to treat hypertension and heart failure for many years. In this study, it was aimed to determine the antimicrobial activity of L-captopril on Methicillin-Resistant Staphylococcus aureus MRSA and Methicillin-Sensitive Staphylococcus aureus (MSSA) clinical isolates and, demonstrate the combination activity of captopril with ciprofloxacin (CXP) and gentamicin (GEN), which are among antistaphylococcal chemical agents.
Method: The minimum inhibitor concentration (MIC) and minimum bactericidal concentration (MBC) were determined using the microdilution technique in 96-well microtiter plates. The activity of L-captopril and CXP or GEN combination against MRSA and MSSA clinical isolates was determined by the micro-broth checkerboard assay method.
Results: The captopril MIC value was determined to be 2.5 mg/ml in all bacteria strains tested. The captopril/CXP combination had an indifferent effect in the other strains tested except for one MRSA isolate. The captopril/GEN combination had an antagonistic effect in all strains studied and increased the MIC 2-4 fold. The captopril/GEN combination was found to reduce the bactericidal activity of gentamicin.
Conclusions: The study results suggest that exposure to these drugs may lead to multidrug resistance in S. aureus bacteria. Especially in the hypertensive patient group, the induced resistance in any S. aureus infections should be taken into consideration while using captopril and, it should be considered that this antagonism may cause an increase in S. aureus infections.

Keywords

References

  1. 1. Taylor TA, Unakal CG, Staphylococcus aureus. In: StatPearls. Treasure Island: StatPearls Publishing; 2021.
  2. 2. Vuong C, Yeh AY, Cheung GY, Otto M. Investigational drugs to teart methicillin-resistant Staphylococcus aureus. Expert. Opin. Investig. Drugs 2015; 4: 1-21.
  3. 3. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler Jr VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28(3): 603-61.
  4. 4. Bush K. Proliferation and significance of clinically relevant β‐lactamases. Annals of the New York Academy of Sciences 2013; 1277(1): 84-90.
  5. 5. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339(8): 530-32.
  6. 6. Chong YP, Park SJ, Bang KM, Kim SH, Lee SO, Choi SH, et al. Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin‐susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome. Eur J Clin Microbiol Infect Dis 2015; 34(2): 349-55.
  7. 7. Cushman DW, Ondetti MA. Design of angiotensin converting enzyme inhibitors. Nature Medicine 1999; 5(10): 1110-1112.
  8. 8. Yusof Y, Tan D, Arjomandi O, Schenk G, McGeary R. Captopril analogues as metallo-β-lactamase inhibitors. Bioorg Med Chem Lett 2016; 26: 1589-1593.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

March 30, 2022

Submission Date

January 29, 2022

Acceptance Date

March 8, 2022

Published in Issue

Year 1970 Volume: 44 Number: 1

AMA
1.Aslan R, Taşkın Kafa AH. Antagonism Between Antibiotics Frequently Used in The Treatment of Staphylococcus aureus Infections and The Hypertensive Drug L-Captopril. CMJ. 2022;44(1):17-21. doi:10.7197/cmj.1064847